An initial trial suggests lamivudine, an inexpensive oral drug for treating HIV, can improve vision in patients with diabetic ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Diabetes is a chronic condition where the body cannot regulate blood sugar levels. This occurs when the body either doesn't ...

Telangiectatic capillaries may have potential clinical relevance for diagnosis and treatment of diabetic macular edema.

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

In patients with diabetic retinopathy, obstructive sleep apnea increases the risk for proliferative diabetic retinopathy, intravitreal injection, and stroke.

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.